Physician profile
Gerald E Peters
NPI 1891703021
$2,792.19
in general payments reported to CMS, 2019-2025
23 companies · $707 in 2025
The $707 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $25.29 · 2021: $336 · 2022: $248 · 2023: $282 · 2024: $1,013 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,003.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,276.47 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $336.42 | 2019-2025 | Libtayo |
| Janssen Biotech, INC. | $139.26 | 2020-2023 | Stelara, Simponi Aria, Simponi |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 | |
| Amgen INC. | $107.41 | 2021-2023 | Otezla |
| Organon LLC | $95.26 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $95.18 | 2021-2025 | |
| Dermavant Sciences, INC. | $81.38 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $74.39 | 2023-2025 | Zoryve |
| Incyte Corporation | $73.46 | 2022-2023 | Opzelura |
| Integra Lifesciences Corporation | $64.91 | 2019 | |
| Smith+Nephew, INC. | $53.59 | 2021-2022 | |
| Leo Pharma INC. | $50.47 | 2021-2022 | |
| Ucb, INC. | $48.81 | 2023 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $32.88 | 2023 | Sotyktu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biowound Solutions, INC. | $31.86 | 2025 | Bio-Connekt |
| Lilly USA, LLC | $20.88 | 2023 | Olumiant, Taltz |
| Kyowa Kirin, INC. | $17.96 | 2023 | Poteligeo |
| Abbvie INC. | $16.70 | 2024 | |
| Novartis Pharmaceuticals Corporation | $13.88 | 2021 | |
| Biofrontera INC. | $12.79 | 2019 | |
| Genentech USA, INC. | $12.23 | 2020 | |
| Organogenesis INC. | $11.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.